Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers

Protein-Based Classifier to Predict Conversion from Clinically Isolated Syndrome to Multiple Sclerosis

“…Finally, protein combination A1AG1ϩAACT-2 also resulted in an acceptable protein classifier but with less sensitivity and specificity than the best two protein combinations. Nonetheless, it is worth noting that the present study has confirmed that both proteins exhibit higher abundances in CDMS patients, as was previously suggested (20,24,42).…”

Effects of Natalizumab Treatment on the Cerebrospinal Fluid Proteome of Multiple Sclerosis Patients

“…were not included 10 . The neurodegeneration-related proteins, alpha-1 antichymotrypsin, contactin-1, neuronal cell adhesion molecule and neural cell adhesion molecule 1, which Ottervald et al described as significantly less abundant after six months of treatment, but not after twelve months treatment, were not significantly differentially abundant after twelve months of natalizumab treatment in our study.…”

“…As a consequence, a reduction of inflammation and inflammatory mediators might be observable in the central nervous system of natalizumab treated patients. However, neurodegeneration-related proteins were recently also reported to be influenced by natalizumab treatment 10 .…”

Biomarkers of Encephalitis

“…In recent years there are more and more studies using those techniques to discover biomarkers in neurological conditions and neurodegenerative diseases (e.g. multiple sclerosis and Alzheimer's disease) (Craig-Schapiro et al 2010; Ottervald et al 2010;Perrin et al 2011). Unbiased proteomics profiling is very complex and requires a multi-discipline approach from sample preparation and protein identification to data processing and validation.…”